Meet with our product experts in one-on-one virtual sessions

Set Up a Meeting
Conexión rápida

Nota informativa

Tech sheet: Dr. Reddy's Bempedoic Acid API Offerings

2022

Tech sheet: Dr. Reddy's Bempedoic Acid API Offerings

Tech sheet: Dr. Reddys Olaparib API Offerings

2022

Tech sheet: Dr. Reddy's Olaparib API Offerings

Tech sheet: Dr. Reddy's Enzalutamide API Offerings

2022

Tech sheet: Dr. Reddy's Enzalutamide API Offerings

Semaglutide - Dr. Reddy’s Fully Synthetic Peptide API

2022

Semaglutide - Dr. Reddy’s Fully Synthetic Peptide API

Our Peptide API Capabilities and Services throughout the product life cycle

2022

Our Peptide API Capabilities and Services throughout the product life cycle

Tech Sheet - Dr. Reddy’s Eribulin Mesylate API offerings

2022

Tech Sheet - Dr. Reddy’s Eribulin Mesylate API offerings

Tech Sheet – Dr. Reddy’s Fexofenadine API offerings

2022

Tech Sheet – Dr. Reddy’s Fexofenadine API offerings

Tech Sheet - Dr. Reddy’s Azacitidine API offerings

2022

Tech Sheet - Dr. Reddy’s Azacitidine API offerings

Tech Sheet - Dr. Reddy’s Ramipril API offerings

2022

Tech Sheet - Dr. Reddy’s Ramipril API offerings

Tech Sheet: Dr. Reddy’s Abiraterone Acetate API offerings

2021

Tech Sheet: Dr. Reddy’s Abiraterone Acetate API offerings

Remdesivir

2021

Formulación de Remdesivir desarrollado en Dr. Reddy’s conforme ala licencia de Gilead:

Whitepaper : Dr.Reddy's 2 DG- A promising treatment in hospitalized COVID-19 patients

2021

Libro blanco: 2 DG de Dr. Reddy’s - Un tratamiento prometedor para pacientes hospitalizados con COVID-19.

Techsheet: Dr.Reddy's Lenvatinib API offerings

2021

Techsheet: Dr.Reddy's Lenvatinib API offerings

ROXADUSTAT - a multipronged development strategy

2021

ROXADUSTAT – una estrategia de desarrollo multidisciplinario

Dr.Reddy's Apremilast API and finished formulation offerings.

2021

Dr.Reddy's Apremilast API and finished formulation offerings.

Dr. Reddy’s Fosaprepitant API offerings

2021

Dr. Reddy’s Fosaprepitant API offerings

Apixaban API – ready-to-compress granules and finished dosage forms

2021

IFA de Apixaban – grageas y formas farmacéuticas terminadas listas para comprimir.

Apalutamide API – an attractive NCE-1 opportunity for generic pharma companies

2021

Los IFA de Apalutamide – una oportunidadatractiva de NCE-1para las compañías farmacéuticas genéricas.

Colloidal Iron Complex Formulations – Understanding and Developing the Process

2021

Formulaciones Coloidales de Hierro Complejas – Entendimiento y Desarrollo del Proceso

Rivaroxaban from Dr.Reddy’s: Full basket offerings of API and Finished formulations

2021

Rivaroxaban de Dr. Reddy’s: Canasta llena de ofertas de IFA y Formulaciones terminadas.

Dr. Reddy's Mirabegron API offering in both alpha and amorphous form

2021

Oferta de IFA de Mirabegron de Dr. Reddy's en fórmulas alfa y amorfo.

Palbociclib – how a novel process development approach provides IP advantages

2021

Palbociclib – cómo un enfoque desarrollista de un proceso innovador provee ventajas de IP.

Dr. Reddy's Elagolix API offering leverages a well rounded Quality by Design approach

2020

La oferta de IFA de Elagolix de Dr. Reddy’s promueve un Enfoque de total Calidad por Diseño.

Sacubitril/Valsartan (LCZ696) – Bringing yet another advantage through innovative API offerings

2020

Sacubitril/Valsartan (LCZ696) – Bringing yet another advantage through innovative API offerings

Dr. Reddy’s Flow Chemistry experts share their perspectives in panel discussion of Chemistry Today

2020

Los expertos en Química de Flujo de Dr. Reddy’s comparten sus perspectivas en el panel de debate de la revista Chemistry Today.

A closer look on how Dr. Reddy's met the stringent regulatory requirement of genotoxic impurities in Ranolazine

2020

Un estudio detallado de cómo Dr. Reddy’s cumplió con los rigurosos requisitos regulatorios de las impurezas genotóxicas en la Ranolazina.

Famotidine and Nizatidine APIs: NDMA controlled, customized particle distribution, supply chain security

2020

API de Famotidina y Nizatidina:NDMA (N-nitrosodimetilamina) controlada, distribución de partícula personalizada, seguridad en cadena de suministro

Sugammadex Sodium – The impact of an integrated understanding from API to formulation on injectable formulation success

2020

Sugammadex Sódico – El impacto de un entendimiento integrado desde los IFA a la formulación de una formulación inyectable exitosa

Meeting the New Regulatory Requirements in Sartan API Production

2019

Cumplimiento de los Nuevos Requisitos Regulatorios en la Producción de IFA de Sartán.

X

API
Active Pharmaceutical Ingredients

API Supplier of the Year

Global Generics & Biosimilars Awards 2021 winner for 3 consecutive years!

Explore our Products